Evaluation of Vaccine Efficacy, Safety and Immunogenicity against Influenza, RSV and COVID-19
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Efficacy and Safety".
Deadline for manuscript submissions: 30 June 2025 | Viewed by 714
Special Issue Editor
Interests: COVID; vaccine; influenza; RSV
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Prophylactic vaccines against influenza and COVID-19 have been given to billions of individuals repeatedly and are effective for the prevention of severe disease. While the safety and efficacy of current influenza vaccines are established based on decades of use, new vaccine concepts to achieve higher efficacy, protection against infection and preferentially more universal protection have a yet-to-be-defined immunogenicity, safety and efficacy profile. Some of these new vaccine concepts have been used for the rapidly developed and licensed COVID-19 vaccines. These have shown to be safe, with a high efficacy against severe disease; however, safety concerns about rare cases of myocarditis, Guillain–Barré syndrome (GBS) and vaccine-induced immune thrombotic thrombocytopenia (VITT) became apparent shortly after vaccination, requiring further research to understand their etiology and long-term consequences. Recently, after decades of RSV, disease-targeting vaccines have been approved and are either based on more traditional subunits or mRNA technology. Understandings of long-term efficacy, immunogenicity and safety are limited and will add to our understanding of effective vaccines against viral respiratory infections.
In this Special Issue, we will collect original research on the immunogenicity, efficacy and safety evaluations of vaccines against influenza, RSV and SARS-CoV-2, preclinical and clinical research with candidate or licensed vaccines and long-term follow-up studies.
Dr. Roland Zahn
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- influenza
- respiratory syncytial virus (RSV)
- COVID-19
- SARS-CoV-2
- vaccines
- immunogenicity
- efficacy
- safety
- universal vaccine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
